Nimbex Adverse Reactions

Data from pooled internal clinical trials were used to determine the frequency of very common to uncommon adverse reactions.
The following convention has been used for the classification of frequency: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1000 to <1/100), rare (≥ 1/10,000 to <1/1000), very rare (< 1/10,000).
Clinical Trial Data: Cardiac disorders: Common: Bradycardia.
Vascular disorders: Common: Hypotension. Uncommon: Cutaneous flushing.
Respiratory, thoracic and mediastinal disorders: Uncommon: Bronchospasm.
Skin and subcutaneous tissue disorders: Uncommon: Rash.
Post-Marketing Data: Immune system disorders: Very rare: Anaphylactic reaction.
Anaphylactic reactions of varying degrees of severity have been observed after the administration of neuromuscular blocking agents. Very rarely, severe anaphylactic reactions have been reported in patients receiving Cisatracurium (Nimbex) in conjunction with one or more anaesthetic agents.
Musculoskeletal and connective tissue disorders: Very rare: Myopathy, muscle weakness.
There have been some reports of muscle weakness and/or myopathy following prolonged use of muscle relaxants in severely ill patients in the ICU. Most patients were receiving concomitant corticosteroids. These events have been reported infrequently in association with Cisatracurium (Nimbex) and a causal relationship has not been established.